There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Acorda Therapeutics Inc. (ACOR) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$0.0186, or +6.00%, to $0.3286. Volume reached 9,507 shares, with price reaching a high of $0.31 and a low of $0.3. The stock was recently discussed on Yahoo Finance as it revealed that Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference.
As a NASDAQ listed company, ACOR falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.33 and fluctuated between $0.3300 as its day high and $0.2766 as its day low. The current market capitalization of Acorda Therapeutics Inc. is $9.41M. A total of 1.05 million shares were traded on the day, compared to an average of 309.63K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, ACOR has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 1 SELLs from insiders. Insiders purchased 0 shares during that period but sold 2,289.
In the most recent transaction, COHEN RON sold 2,289 shares of ACOR for 1.70 per share on Mar 17. After the transaction, the President and CEO now owns 129,601 company shares.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for ACOR in the last 3 months, the mean price target is $10.00 with high estimates of $10.00 and low estimates of $10.00. In terms of 52-week highs and lows, ACOR has a high of $4.99 and a low of $0.28.
The company reported an EPS of $-2.78 in the last quarter, which was -672.22% lower than expectations of $-0.36.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACOR is Buy with a score of 0.00. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.